Hardman Johnston Global Advisors LLC Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

Hardman Johnston Global Advisors LLC decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,271 shares of the life sciences company’s stock after selling 1,565 shares during the quarter. Hardman Johnston Global Advisors LLC’s holdings in Illumina were worth $8,512,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Illumina by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after purchasing an additional 66,528 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Illumina by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after buying an additional 204,043 shares during the last quarter. Capital World Investors grew its holdings in Illumina by 41.1% in the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after buying an additional 801,814 shares in the last quarter. Primecap Management Co. CA increased its stake in shares of Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after acquiring an additional 1,997,010 shares during the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd raised its holdings in shares of Illumina by 1.1% during the 1st quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company’s stock worth $284,097,000 after acquiring an additional 22,067 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 1.0 %

Shares of NASDAQ:ILMN opened at $154.96 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $156.66. The stock has a market cap of $24.69 billion, a price-to-earnings ratio of -15.56 and a beta of 1.13. The firm’s 50 day moving average price is $136.87 and its 200 day moving average price is $122.92.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the firm posted $0.33 EPS. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, equities research analysts predict that Illumina, Inc. will post 3.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on ILMN. TD Cowen raised their price objective on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday. Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a report on Wednesday, August 28th. JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Finally, Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a research report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $161.50.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.